NewAmsterdam Pharma Company N.V.
NASDAQ: NAMS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael Davidson
- Employees
- 100
- Headquarters
- Naarden, Netherlands
- IPO year
- 2021
- Market cap
- $4.1B
- Website
- https://www.newamsterdampharma.com
Loading NAMS…
Loading profile data…Frequently asked questions about NAMS
What does NewAmsterdam Pharma Company N.V. (NAMS) do?
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ez...
Where does NAMS trade?
NewAmsterdam Pharma Company N.V. (NAMS) trades on the NASDAQ.
What sector is NAMS in?
NewAmsterdam Pharma Company N.V. (NAMS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of NewAmsterdam Pharma Company N.V.?
Michael Davidson is the chief executive officer of NewAmsterdam Pharma Company N.V. (NAMS).
Where is NewAmsterdam Pharma Company N.V. headquartered?
NewAmsterdam Pharma Company N.V. is headquartered in Netherlands.
Does NAMS pay a dividend?
NewAmsterdam Pharma Company N.V. (NAMS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NAMS go public?
NewAmsterdam Pharma Company N.V. (NAMS) completed its initial public offering in 2021.